Registration Dossier

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
sub-chronic toxicity: oral
Type of information:
experimental study
Adequacy of study:
supporting study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: No OECD guideline or GLP study. Only bw. and mortality examined.
Cross-reference
Reason / purpose for cross-reference:
reference to same study

Data source

Reference
Reference Type:
publication
Title:
Bioassay of 1,5-Naphthylenediamine for possible carcinogenicity; CAS No. 2243-62-1; NCI-CG-TR-143
Author:
National Cancer Institute (NCI)
Year:
1978
Bibliographic source:
National Cancer Institute; CARCINOGENESIS; Technical Report Series, No. 143, 1978

Materials and methods

Principles of method if other than guideline:
Method: other: dose-finding study
GLP compliance:
not specified
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
1,5-naphthylenediamine
EC Number:
218-817-8
EC Name:
1,5-naphthylenediamine
Cas Number:
2243-62-1
Molecular formula:
C10H10N2
IUPAC Name:
1,5-naphthylenediamine
Constituent 2
Reference substance name:
1,5- naphthylenediamine
IUPAC Name:
1,5- naphthylenediamine
Details on test material:
IUCLID4 Test substance: other TS: purity 89-90 % (chromatography indicated an impurity)

Test animals

Species:
mouse
Strain:
B6C3F1
Sex:
male/female

Administration / exposure

Route of administration:
oral: feed
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
8 weeks
Frequency of treatment:
continuously in diet
Doses / concentrations
Remarks:
Doses / Concentrations:
0.03, 0.1, 0.3, 1.0 or 3.0 % (ca. 43, 143, 429, 1429 or 4286 mg/kg/d)
Basis:

No. of animals per sex per dose:
5/sex/dose
Control animals:
yes, concurrent no treatment

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Mortality:
mortality observed, treatment-related
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
not specified
Clinical biochemistry findings:
not specified
Urinalysis findings:
not specified
Behaviour (functional findings):
not specified
Organ weight findings including organ / body weight ratios:
not specified
Gross pathological findings:
not specified
Histopathological findings: non-neoplastic:
not specified
Histopathological findings: neoplastic:
not specified

Effect levels

Basis for effect level:
other: see: executive summary
Remarks on result:
not measured/tested
Remarks:
Effect level not specified (migrated information)

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

RS-Freetext:
in all groups receiving 0.3 % or more deaths occurred and
also in females applied 0.03 %; in the group receiving 0.3 %
mean body weight depression was 22 % in males and 3 % in
females; males receiving 0.1 % showed a mean body weight
depression of ca. 3 %, while the females had a greater body
weight than the controls

Applicant's summary and conclusion

Executive summary:

In order to establish the maximum tolerated concentrations of the test substance for administration to dosed animals in a chronic study, a subchronic toxicity study was conducted with B6C3F1 mice of both sexes.

The concentrations used were: 0,03; 0,1; 0,3; 1,0 and 3,0 %. The dosed dietary preparations were administered for 8 weeks.

Deaths were recorded for all groups of mice receiving concentrations of 0,3 % or more (no Nr. of animals given).

Mean body weight depression was approximately 22 and 3 %, respectively, in males and females dosed with 0,3 % of test substance.

Males receiving 0,1 % experienced mean body weight depression of approximately 3 %.

The concentration of test substance selected as highest dose group for the in the mouse chronic bioassay was 0,2 %.